Dr Lal PathLabs buys 70% of genomics firm SN Gene for up to $18M
What's the deal? Dr Lal PathLabs, an Indian diagnostic services provider, will acquire a 70% stake in genomics firm SN GeneDealroom has a profile for this one. Try Dealroom → for up to US$22.8M in cash. Its board approved the deal on September 24, along with a performance-linked earn-out capped at US$4.28M.
The purchase, made from SN Gene's existing shareholders, will turn the company into a subsidiary of Dr Lal PathLabs. It is expected to close by November 30, 2026, and needs no regulatory approvals.
What's the endgame? Dr Lal PathLabs said the goal is to strengthen its expertise in genomics and broaden its portfolio of advanced diagnostic services. SN Gene, incorporated in Gujarat in 2013, provides genomics diagnostic services.
By the numbers: SN Gene posted turnover of US$7.87M in FY26, up from US$7.25M in FY25 and US$5.88M in FY24 — steady growth that underpins its appeal as an acquisition target.
Shares of Dr Lal PathLabs closed at US$26.6 on the BSE, up 1.88% on the day.
The signal: The deal reflects a wider push by established diagnostics players to move into higher-value genomics testing, adding specialised capabilities through acquisition rather than building them in-house.
Image credit: kaibara87
